Hydreight Tech Stock Price, News & Analysis

Hydreight Technologies (OTC: HYDTF), a mobile clinical network with a proprietary telehealth platform, reported exceptional growth in August 2025, processing over 80,000 pharmacy and telehealth product orders, significantly exceeding internal forecasts of 55,000 orders.

Key achievements include 33% year-over-year revenue growth in H1 2025, marking the third consecutive profitable quarter. The company added 528 new nurse licenses (72% YoY increase) and saw pharmacy orders surge 86% year-over-year from January to August 2025.

Strategic developments include closing an oversubscribed $11.5M convertible debenture financing, acquiring a 5% stake in Perfect Scripts LLC (with option to increase to 40%), and pursuing AI integration through the planned acquisition of Dynamic IV Therapy Support AI Agent.

Hydreight Technologies (OTC: HYDTF), a nationwide digital healthcare solutions provider, has successfully closed its oversubscribed private placement of unsecured convertible debentures, raising C$11.5 million including the full exercise of the over-allotment option.

The debentures, issued at C$1,000 each, will mature on September 4, 2028, carrying a 9.0% annual interest rate. They are convertible into common shares at C$4.06 per share, with interest payable semi-annually. The company maintains a forced conversion right if the stock trades above C$5.08 for 20 consecutive trading days.

CEO Shane Madden highlighted the company's recent achievement of profitability in Q2 and plans to use the proceeds for general corporate and working capital purposes to accelerate growth.

Hydreight Technologies (OTCQB:HYDTF), a mobile clinical network and medical platform, reported strong financial results for Q2 2025, marking its third consecutive quarter of profitability. The company achieved Q2 GAAP revenue of $5.38 million, up 31% year-over-year, and H1 2025 revenue of $9.92 million, representing a 33% increase.

Key performance metrics include Q2 Gross Margin of $1.93 million, Adjusted EBITDA of $182K, and GAAP Net Income of $50K. The company saw significant growth with a 77% increase in new nurse signups and 48% growth in pharmacy orders compared to Q2 2024.

Hydreight announced a strategic initiative to acquire a 5% equity stake in Perfect Scripts, LLC with an option to increase to 40%, and launched a C$10 Million Convertible Debenture Offering to support growth and M&A activities.

Hydreight Technologies (OTC: HYDTF) reported exceptional growth in its VSDHOne platform, with July orders reaching 35,642 SKUs - more than triple the projected 10,000 orders. The company is now targeting 55,000 SKU orders for August as it progresses toward its 2025 goal of 1.3 million total orders.

The company announced a strategic partnership with Perfect Scripts, gaining access to 503B outsourcing facilities for large-batch drug compounding. This integration enables nationwide API connectivity, automated prescription processing, and enhanced fulfillment capabilities. Additionally, Hydreight launched its Marketing Solutions subsidiary to provide turnkey marketing services to licensees and telehealth partners.

The company also announced the resignation of director Gabi Kabazo, effective August 8, 2025.

Hydreight Technologies (OTCQB: HYDTF), a telehealth and mobile medical services company, has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025, in Boston. CEO Shane Madden and Board Chair Shafin Diamond Tejani will represent the company, discussing its growth strategy and new offerings.

The company will also host an investor webinar on July 24, 2025, focusing on the Perfect Scripts Acquisition. Notably, Hydreight reported 34% year-over-year revenue growth in Q1 and was recently ranked as the #56 fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™.

Hydreight Technologies (HYDTF) reported strong Q1 2025 financial results with 34% year-over-year revenue growth. The company achieved topline revenue of $6.53M and GAAP revenue of $4.54M, up from $3.38M in Q1 2024. Notably, Hydreight reached profitability with GAAP Net Income of $21K, compared to a $309K loss in Q1 2024, and Adjusted EBITDA of $163K. The company saw significant operational growth with a 65% increase in new nurse signups and 48% growth in pharmacy orders. Hydreight completed a strategic financing of $5.4M gross in February and launched new services including Personalized Genetic Testing and Wellness Solution on their VSDHOne Platform. The company maintains a strong cash position of $6.04M and continues to expand its mobile clinical network across 50 US states.

Hydreight Technologies (HYDTF) has launched a new direct-to-consumer genetic testing and personalized wellness solution on its VSDHOne platform. The service provides at-home DNA testing kits and personalized health plans based on genetic profiles. Key features include genetic sequencing, personalized recommendations, licensed prescriber review, and nationwide fulfillment. The service will be available through Hydreight's network of 3,000+ nurses, 200+ physicians, and 400+ D2C brands. The offering follows a subscription-based model, generating upfront revenue from testing and recurring monthly revenue from health regimens and supplement delivery. According to industry reports, the global consumer genomics market is expected to reach $50 billion by 2030, with the at-home testing market projected to exceed $15 billion by 2028. This launch aligns with Hydreight's 2025 priorities, including expanding white-label services and scaling D2C brand onboarding.

Hydreight Technologies (HYDTF) announced its participation in two upcoming investor conferences in June 2025: Maxim Group's Virtual Tech Conference (June 3-5) and the CEM Bermuda Capital Event (June 6-8). The company recently reported strong FY2024 financial results, including: • Adjusted Revenue of $22.32M CAD (↑31% YoY) • GAAP Revenue of $16.04M CAD (↑39% YoY) • Positive Adjusted EBITDA of $490K CAD • Cash Flow from Operations: $857K CAD • Cash Position: $6.8M CAD The digital health platform expanded its services in 2024 to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications. Hydreight operates across all 50 states with over 400 D2C brands and a network of 3,000+ nurses and 200+ physicians.

Hydreight Technologies (OTCQB: HYDTF) has appointed Dr. Jeremy Roebuck as a director of the company, effective May 5, 2025. Dr. Roebuck, who has served on Hydreight's Board of Advisors since December 12, 2022, fills the vacancy created by the resignation of Alexandros Tzilios. Hydreight is a North American integrated mobile clinical network of nurses, doctors, and pharmacy distribution.

Dr. Roebuck expressed enthusiasm about joining the board at a crucial growth phase, highlighting the company's focus on delivering healthcare through a compliant, tech-enabled platform. He aims to contribute to scaling the platform and expanding Hydreight's presence across North America.